142 related articles for article (PubMed ID: 7478616)
1. Loss of transcriptional attenuation in N-myc is associated with progression towards a more malignant phenotype.
Xu L; Meng Y; Wallen R; DePinho RA
Oncogene; 1995 Nov; 11(9):1865-72. PubMed ID: 7478616
[TBL] [Abstract][Full Text] [Related]
2. Role of first exon/intron sequences in the regulation of myc family oncogenic potency.
Xu L; Wallen R; Patel V; DePinho RA
Oncogene; 1993 Sep; 8(9):2547-53. PubMed ID: 8361763
[TBL] [Abstract][Full Text] [Related]
3. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
Choe C; Chen N; Sawadogo M
Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line.
Himelstein BP; Lee EJ; Sato H; Seiki M; Muschel RJ
Oncogene; 1997 Apr; 14(16):1995-8. PubMed ID: 9150367
[TBL] [Abstract][Full Text] [Related]
5. Differential effects by Mad and Max on transformation by cellular and viral oncoproteins.
Cerni C; Bousset K; Seelos C; Burkhardt H; Henriksson M; Lüscher B
Oncogene; 1995 Aug; 11(3):587-96. PubMed ID: 7630643
[TBL] [Abstract][Full Text] [Related]
6. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
[TBL] [Abstract][Full Text] [Related]
7. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation.
Greenberg RA; O'Hagan RC; Deng H; Xiao Q; Hann SR; Adams RR; Lichtsteiner S; Chin L; Morin GB; DePinho RA
Oncogene; 1999 Feb; 18(5):1219-26. PubMed ID: 10022128
[TBL] [Abstract][Full Text] [Related]
8. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
[TBL] [Abstract][Full Text] [Related]
9. Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation.
Hartl M; Bister K
Oncogene; 1998 Dec; 17(22):2901-13. PubMed ID: 9879996
[TBL] [Abstract][Full Text] [Related]
10. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions.
Koskinen PJ; Ayer DE; Eisenman RN
Cell Growth Differ; 1995 Jun; 6(6):623-9. PubMed ID: 7669717
[TBL] [Abstract][Full Text] [Related]
11. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells.
Su ZZ; Austin VN; Zimmer SG; Fisher PB
Oncogene; 1993 May; 8(5):1211-9. PubMed ID: 8479744
[TBL] [Abstract][Full Text] [Related]
12. Functional analysis of the carboxy-terminal transforming region of v-Myc: binding to Max is necessary, but not sufficient, for cellular transformation.
Min S; Mascarenhas NT; Taparowsky EJ
Oncogene; 1993 Oct; 8(10):2691-701. PubMed ID: 8378081
[TBL] [Abstract][Full Text] [Related]
13. c-fos is a positive regulator of carcinogen enhancement of adenovirus transformation.
Su ZZ; Yemul S; Stein CA; Fisher PB
Oncogene; 1995 May; 10(10):2037-49. PubMed ID: 7761104
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
15. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours.
Fourel G; Trepo C; Bougueleret L; Henglein B; Ponzetto A; Tiollais P; Buendia MA
Nature; 1990 Sep; 347(6290):294-8. PubMed ID: 2205804
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene.
Vasseur S; Malicet C; Calvo EL; Labrie C; Berthezene P; Dagorn JC; Iovanna JL
Mol Cancer; 2003 Mar; 2():19. PubMed ID: 12685932
[TBL] [Abstract][Full Text] [Related]
17. A protein binding site from the murine c-myc promoter contributes to transcriptional block.
Dufort D; Drolet M; Nepveu A
Oncogene; 1993 Jan; 8(1):165-71. PubMed ID: 8423994
[TBL] [Abstract][Full Text] [Related]
18. In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells.
Lutz W; Schwab M
Oncogene; 1997 Jul; 15(3):303-15. PubMed ID: 9233765
[TBL] [Abstract][Full Text] [Related]
19. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
Marcotte R; Chen JM; Huard S; Wang E
J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
[TBL] [Abstract][Full Text] [Related]
20. BRCA1 binds c-Myc and inhibits its transcriptional and transforming activity in cells.
Wang Q; Zhang H; Kajino K; Greene MI
Oncogene; 1998 Oct; 17(15):1939-48. PubMed ID: 9788437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
